- Home
- SAFT vs CVAC Comparison
SAFT vs CVAC Comparison
Compare SAFT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAFT | CVAC |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAFT | CVAC |
|---|---|---|
| Price | $75.80 | $4.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 90.0K | ★ 1.2M |
| Earning Date | 11-03-2025 | 11-24-2025 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | 15.78 | ★ 94.02 |
| EPS | ★ 5.87 | 0.94 |
| Revenue | ★ $1,231,116,000.00 | $83,000,117.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.71 |
| P/E Ratio | $13.27 | ★ $4.83 |
| Revenue Growth | ★ 12.77 | N/A |
| 52 Week Low | $67.04 | $2.48 |
| 52 Week High | $84.20 | $5.72 |
Technical Indicators
Market Signals| Indicator | SAFT | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 48.10 |
| Support Level | $78.10 | $4.26 |
| Resistance Level | $79.26 | $4.36 |
| Average True Range (ATR) | 1.45 | 0.17 |
| MACD | -0.39 | 0.03 |
| Stochastic Oscillator | 0.42 | 57.32 |
Price Performance
Historical ComparisonAbout SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.